Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 52:1628-1636, doi:10.1016/j.jacc.2008.08.041
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by García Rodríguez, L. A.
Right arrow Articles by Patrignani, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by García Rodríguez, L. A.
Right arrow Articles by Patrignani, P.
Related Collections
Right arrowRelated Articles

Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population

Luis Alberto García Rodríguez, MD*,*, Stefania Tacconelli, PhD{dagger} and Paola Patrignani, PhD{dagger}

* Centro Español de Investigación Farmacoepidemiológica (CEIFE), Madrid, Spain
{dagger} Department of Medicine and Center of Excellence on Aging, G. d'Annunzio University, School of Medicine, CeSI, Chieti, Italy


Figure 1
View larger version (46K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Degree of Inhibition of COX-2 by Average Circulating Concentrations of Individual NSAIDs Functionally Selective for COX-2 Is Relevant to RR of Nonfatal MI

(A) Relative risk (RR) and 95% confidence interval (CI) of MI according to use of individual nonsteroidal anti-inflammatory drugs (NSAIDs). (B) Effects of therapeutic concentrations of NSAIDs on whole blood COX-1 (blue bars), mostly from platelets, and COX-2 (green bars), mostly from monocytes, in vitro. The dotted line represents the functional range of inhibition of platelet COX-1, namely, ≥95% (9). (C) Relationship between degree of inhibition of whole blood COX-2 and RR of MI by individual NSAIDs. Naproxen, which affects platelet COX-1 activity at functional range, is not shown. The linear regression analysis yielded a significant correlation between the 2 variables. It was performed using InStat (GraphPad, San Diego, California). Cele = celecoxib; Diclo = diclofenac; Etod = etodolac; Etori = etoricoxib; Ibu = ibuprofen; Indo = indomethacin; Melo = meloxicam; Piro = piroxicam; Rofe = rofecoxib.

 

Figure 2
View larger version (13K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Effect of Daily Dose and Formulation of Diclofenac on RR of Nonfatal MI

Effect of the daily dose and formulation (slow release compared with plain) of diclofenac on relative risk (RR) of nonfatal myocardial infarction (MI) is shown. The RR and 95% confidence interval of MI according to daily dose of diclofenac are compared with nonuse and stratified by presentation form.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement